| Mar-21-19 08:00AM | DURECT Announces Patient Dosing in Phase 2a Proof-of-Concept Clinical Trial of Topical DUR-928 in Patients with Mild to Moderate Plaque Psoriasis PR Newswire |
| Mar-13-19 07:55PM | Edited Transcript of DRRX earnings conference call or presentation 7-Mar-19 9:30pm GMT Thomson Reuters StreetEvents |
| 04:00PM | DRRX: DUR-928 Programs Accelerating. Anticipate NASH, Psoriasis Data Later This Year Zacks Small Cap Research |
| Mar-08-19 09:48PM | Durect Corp (DRRX) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com |
| Mar-07-19 04:05PM | DURECT Corporation Announces Fourth Quarter and Full Year 2018 Financial Results and Update of Programs PR Newswire -5.79% |
| Mar-04-19 08:00AM | DURECT Corporation Invites You to Join its Fourth Quarter 2018 Earnings Conference Call PR Newswire -5.43% |
| Feb-27-19 07:00AM | DURECT Announces Plans to Submit to FDA a Full Response to the POSIMIR® Complete Response Letter PR Newswire |
| Feb-26-19 12:00PM | DURECT Corporation (NASDAQ:DRRX): Time For A Financial Health Check Simply Wall St. |
| Feb-22-19 07:20AM | Factors of Influence in 2019, Key Indicators and Opportunity within ARRIS International plc, Edwards Lifesciences, DENTSPLY SIRONA, Vail Resorts, Akers Biosciences, and DURECT New Research Emphasizes Economic Growth GlobeNewswire |
| Feb-21-19 08:00AM | DURECT Corporation to Participate in the Berenberg NASH Day PR Newswire |
| Jan-24-19 07:00AM | Streetwise Reports Examines the Commercial Launch Planned for Schizophrenia Drug GlobeNewswire |
| Jan-11-19 11:45AM | DRRX: Pipeline Update: Focus Is On Accelerating DUR-928 in NASH and Other High-Potential Indications Zacks Small Cap Research |
| Jan-10-19 07:51AM | Edited Transcript of DRRX earnings conference call or presentation 7-Nov-18 9:30pm GMT Thomson Reuters StreetEvents |
| Jan-07-19 07:30AM | DURECT Corporation Provides Corporate Update PR Newswire -13.10% |
| Jan-04-19 06:59AM | Heres What We Think About DURECT Corporations (NASDAQ:DRRX) CEO Pay Simply Wall St. +27.52% |
| Jan-03-19 04:30PM | DURECT Corporation Announces Investor Call to Provide Corporate Update PR Newswire -5.22% |
| Dec-19-18 08:00AM | Commercial Launch Plans Announced for PERSERIS (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults PR Newswire |
| Dec-17-18 08:00AM | DURECT Corporation Announces Retirement of Dr. Felix Theeuwes as Chairman of the Board and Distinguished Scientist PR Newswire |
| Nov-30-18 07:55AM | Analysis: Positioning to Benefit within News Corporation, DURECT, Ecolab, MiX Telematics, Ship Finance International, and BCE Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire -5.67% |
| Nov-19-18 08:00AM | DURECT Announces Amendment to Accelerate Ongoing Phase 2a Trial of DUR-928 in Alcoholic Hepatitis (AH) by Allowing Dosing of Severe AH Patients in Parallel to Moderate AH Patients PR Newswire |
| Nov-16-18 02:30PM | DRRX: Protocol Amendment Speeds DUR-928 Ph2 AH Trial. PERSERIS FDA Approval Adds New Revenue Stream Zacks Small Cap Research |
| Nov-13-18 01:44PM | Could DURECT Corporations (NASDAQ:DRRX) Investor Composition Influence The Stock Price? Simply Wall St. -5.61% |
| Nov-07-18 05:13PM | Durect: 3Q Earnings Snapshot Associated Press +5.19% |
| 04:01PM | DURECT Corporation Announces Third Quarter 2018 Financial Results and Provides Corporate Update PR Newswire |
| Nov-01-18 04:15PM | DURECT Corporation Invites You to Join its Third Quarter 2018 Earnings Conference Call PR Newswire |
| Oct-25-18 08:00AM | DURECT Announces Abstracts on DUR-928 to be Presented at Upcoming Scientific Meetings PR Newswire +7.45% |
| Oct-23-18 08:20AM | Report: Exploring Fundamental Drivers Behind Alder BioPharmaceuticals, DURECT, Mettler-Toledo International, Internap, Career Education, and Approach Resources New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire |
| Oct-01-18 08:00AM | DURECT Corporation Appoints Michael H. Arenberg, J.D., M.B.A. as Chief Financial Officer PR Newswire |
| Sep-25-18 08:00AM | DURECT to Present at the Cantor Fitzgerald Global Healthcare Conference PR Newswire +5.66% |
| Sep-19-18 12:50PM | Is DURECT Corporations (NASDAQ:DRRX) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St. |
| Sep-18-18 08:00AM | DURECT Announces Methydur Sustained Release Capsules Receive Marketing Authorization for ADHD in Taiwan PR Newswire |
| Aug-30-18 08:00AM | DURECT Announces Receipt of $5 Million Milestone Payment from Indivior PR Newswire |
| Aug-27-18 04:30PM | DURECT to Present at the 20th Annual Rodman & Renshaw Global Investment Conference PR Newswire |
| Aug-21-18 07:45AM | Recent Analysis Shows DURECT, Corporacion America Airports S.A., Golden Star Resources, MacroGenics, Merus N.V., and Superior Uniform Group Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire |
| Aug-06-18 03:32PM | FDA Decision Sends Pain Therapeutics Reeling Benzinga |
| 09:22AM | DURECT's Licensee Pain Therapeutics Receives Complete Response Letter from FDA for REMOXY® ER (oxycodone) Extended-Release Capsules CII PR Newswire |
| Aug-01-18 09:14PM | Edited Transcript of DRRX earnings conference call or presentation 1-Aug-18 8:30pm GMT Thomson Reuters StreetEvents |
| 05:42PM | Durect: 2Q Earnings Snapshot Associated Press |
| 04:05PM | DURECT Corporation Announces Second Quarter 2018 Financial Results and Provides Corporate Update PR Newswire |
| Jul-30-18 11:42AM | Why Durect Corporation Stock Is Spiking Today Motley Fool +9.93% |
| 08:00AM | DURECT Announces FDA Approval of Indivior's PERSERIS (risperidone) Extended-Release Injectable Suspension for the Treatment of Schizophrenia in Adults PR Newswire |
| Jul-24-18 04:05PM | DURECT Corporation Invites You to Join its Second Quarter 2018 Earnings Conference Call PR Newswire |
| Jul-22-18 05:03PM | The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trial Results, Earnings And IPOs Benzinga |
| Jul-09-18 07:25AM | Complimentary Technical Snapshots on Teva Pharma Industries and Three More Drug Makers Stocks ACCESSWIRE |
| Jul-05-18 12:25PM | A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year Benzinga +7.64% |
| Jun-30-18 06:05PM | Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates Benzinga |
| Jun-28-18 03:48PM | Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER Zacks -7.06% |
| Jun-27-18 01:29PM | Here's Why Drug Developer DURECT Corporation Plunged Today Motley Fool |
| 08:14AM | Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading Benzinga |
| Jun-26-18 08:30PM | Results of FDA Advisory Committee Meeting for REMOXY® ER PR Newswire -9.38% |
| Jun-25-18 02:00PM | The Week Ahead: Senate Weighs Sprint-T-Mobile Merger, Nike Earnings And A Slew Of IPOs Benzinga |
| Jun-07-18 08:10AM | New Research Coverage Highlights Durect, Credit Suisse Group, Obsidian Energy, TransCanada, Golden Star Resources, and Loxo Oncology Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire |
| 07:50AM | Free Daily Technical Summary Reports on Endo International and Three Other Healthcare Stocks ACCESSWIRE |
| Jun-04-18 08:00AM | DURECT Corporation Approaching PDUFA Dates and Analysts Review ACCESSWIRE |
| May-09-18 08:00AM | DURECT Announces Amendment to Licensing Agreement with Sandoz Related to POSIMIR® (SABER®-Bupivacaine) PR Newswire +7.22% |
| May-08-18 07:23AM | Want To Invest In DURECT Corporation (NASDAQ:DRRX)? Heres How It Performed Lately Simply Wall St. |
| May-07-18 05:19AM | Edited Transcript of DRRX earnings conference call or presentation 2-May-18 8:30pm GMT Thomson Reuters StreetEvents |
| May-02-18 06:23PM | Durect: 1Q Earnings Snapshot Associated Press |
| 04:05PM | DURECT Corporation Announces First Quarter 2018 Financial Results and Provides Corporate Update PR Newswire |
| Apr-25-18 08:00AM | DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Alcoholic Hepatitis PR Newswire |
| Apr-24-18 04:30PM | DURECT Corporation Invites You to Join its First Quarter 2018 Earnings Conference Call PR Newswire |
| Mar-29-18 08:00AM | DURECT Corporation to Host Key Opinion Leader Call on Alcoholic Hepatitis PR Newswire |
| Mar-26-18 07:40AM | Investor Expectations to Drive Momentum within Aon plc, Endeavour Silver, BlackBerry, DURECT, Castle Brands, and Nabors Industries Discovering Underlying Factors of Influence GlobeNewswire -5.80% |
| Mar-20-18 08:00AM | DURECT Announces FDA Advisory Committee Meeting for REMOXY® ER PR Newswire +5.94% |
| Mar-12-18 07:58AM | Is DURECT Corporation (NASDAQ:DRRX) Undervalued? Simply Wall St. |
| Mar-06-18 01:36PM | Analyst: Durect's Phase 2 Trials Are An Entry Point For Investors Benzinga +8.67% |
| Mar-01-18 06:31PM | Durect tops 4Q revenue forecasts Associated Press +8.20% |
| 04:05PM | DURECT Corporation Announces Fourth Quarter and Full Year 2017 Financial Results and Update of Programs PR Newswire |
| Feb-26-18 08:00AM | DURECT Announces Patient Dosing in Phase 2a Trial of DUR-928 in Primary Sclerosing Cholangitis (PSC) PR Newswire +6.19% |
| Feb-22-18 04:30PM | DURECT Corporation Invites You to Join its Fourth Quarter 2017 Earnings Conference Call PR Newswire |
| Feb-20-18 08:00AM | DURECT Corporation to Host Key Opinion Leader Call on Treatment of Primary Sclerosing Cholangitis (PSC) PR Newswire |
| Feb-14-18 08:00AM | DURECT Announces Resubmission of REMOXY® ER New Drug Application by its licensee, Pain Therapeutics PR Newswire |
| Dec-13-17 08:00AM | DURECT Announces NDA Acceptance of Indivior's RBP-7000 Risperidone Monthly Depot PR Newswire |
| Dec-12-17 08:05AM | DURECT Corporation: New Patent Revenue, Analysts Review, Earnings and Current Pipeline Progress ACCESSWIRE |
| Dec-11-17 01:47PM | ETFs with exposure to DURECT Corp. : December 11, 2017 Capital Cube |
| Dec-01-17 10:36AM | ETFs with exposure to DURECT Corp. : December 1, 2017 Capital Cube |
| Nov-20-17 12:15PM | ETFs with exposure to DURECT Corp. : November 20, 2017 Capital Cube +7.92% |
| Nov-15-17 09:00AM | Streetwise Reports Examines How One Analyst Says This Biotech Company Could Potentially 'Double' GlobeNewswire |
| Nov-09-17 08:54AM | DURECT Corp. :DRRX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017 Capital Cube |
| Nov-08-17 05:58PM | ETFs with exposure to DURECT Corp. : November 8, 2017 Capital Cube -6.86% |
| 12:25PM | Edited Transcript of DRRX earnings conference call or presentation 1-Nov-17 8:30pm GMT Thomson Reuters StreetEvents |
| Nov-02-17 05:00PM | DRRX: Focus will be Shifted to DUR-928 Programs Zacks Small Cap Research +10.13% |
| Nov-01-17 05:47PM | Durect tops Street 3Q forecasts Associated Press |
| 04:05PM | DURECT Corporation Announces Third Quarter 2017 Financial Results and Provides Corporate Update PR Newswire |
| Oct-26-17 04:54PM | DURECT Corporation Invites You to Join its Third Quarter 2017 Earnings Conference Call PR Newswire |
| 10:28AM | ETFs with exposure to DURECT Corp. : October 26, 2017 Capital Cube |
| Oct-20-17 09:54AM | DURECT Corporation (DRRX) Shares Collapse Heres Why SmarterAnalyst -60.53% |
| Oct-19-17 05:57PM | DURECT Announces Top-line Results from the PERSIST Phase 3 Trial of POSIMIR® (SABER®-Bupivacaine) Did Not Meet Primary Efficacy Endpoint PR Newswire |
| Oct-16-17 09:51AM | ETFs with exposure to DURECT Corp. : October 16, 2017 Capital Cube +9.34% |
| Oct-05-17 10:58AM | ETFs with exposure to DURECT Corp. : October 5, 2017 Capital Cube |
| 08:45AM | Streetwise Reports Examines Small Biotech That Entered Patent Deal with British Company Targeting Schizophrenia Marketwired |
| Oct-04-17 09:02AM | DURECT Corp. :DRRX-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017 Capital Cube -5.24% |
| Oct-03-17 08:00AM | DURECT (DRRX): A $17.5 Million Patent Purchase Agreement with Indivior PLC Zacks Small Cap Research +12.30% |
| Oct-02-17 02:05AM | DURECT and Indivior PLC Sign a $17.5 Million Patent Purchase Agreement PR Newswire +5.65% |
| Sep-20-17 08:00AM | DURECT Appoints Dr. Myriam Theeuwes as Senior Vice President, Clinical Development PR Newswire |
| Sep-05-17 04:15PM | DURECT to Participate in Upcoming Healthcare Conferences PR Newswire |
| Aug-14-17 08:59AM | Edited Transcript of DRRX earnings conference call or presentation 8-Aug-17 8:30pm GMT Thomson Reuters StreetEvents |
| Aug-10-17 02:00PM | DRRX: A $293 Million Deal with Sandoz for POSIMIR® in the United States Zacks Small Cap Research |
| Aug-08-17 11:56PM | Durect reports 2Q loss Associated Press |
| 04:05PM | DURECT Corporation Announces Second Quarter 2017 Financial Results and Provides Corporate Update PR Newswire |
